Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

Clinical Pharmacokinetics

Volumn 38, Issue 1, 2000, Pages 41-57

  Dresser, George K ^a   Spence, J David ^a   Bailey, David G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ASTEMIZOLE; BUSPIRONE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIAZEPAM; ENZYME INHIBITOR; ERGOTAMINE; ERYTHROMYCIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; MIDAZOLAM; NEFAZODONE; PHOSPHODIESTERASE INHIBITOR; PIMOZIDE; PROTEINASE INHIBITOR; RITONAVIR; SILDENAFIL; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; ZOPICLONE;

AGE; ATAXIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISPOSITION; DRUG INTERACTION; DRUG METABOLISM; DRUG OXIDATION; ENZYME INHIBITION; ENZYME SUBSTRATE; ERGOTISM; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RHABDOMYOLYSIS; SEDATION; SMALL INTESTINE; TORSADE DES POINTES;

EID: 0033972441     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038010-00003     Document Type: Review

References (162)

1. 1. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism [review]. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
2. 2. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-59
3. 3. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans [review]. J Pharmacokinet Biopharm 1996; 24: 475-90
4. 4. Anttila S, Hukkanen J, Hakkola J, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 1997; 16: 242-9
5. 5. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947-55
6. 6. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans [review]. J Clin Pharm Ther 1998; 23: 247-55
7. 7. Paintaud G, Bechtel Y, Brientini MP, et al. Effects of liver diseases on drug metabolism [review]. Therapie 1996; 51: 384-9
8. 8. Iqbal S, Vickers C, Elias E. Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes. J Hepatol 1990; 11: 37-42
9. 9. Kashuba AD, Berlino JSJ, Rocci MLJ, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998; 64: 269-77
10. 10. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
11. 11. Landahl S, Edgar B, Gabrielsson M, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients: a comparison with young healthy subjects. Clin Pharmacokinet 1988; 14: 374-83
12. 12. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-45
13. 13. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions [review]. Br J Clin Pharmacol 1998; 46: 101-10
14. 14. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998; 64: 237-47
15. 15. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61
16. 16. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41
17. 17. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice [review]. Int J Clin Pharmacol Ther 1998; 36: 9-13
18. 18. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-14
19. 19. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944-8
20. 20. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A [review]. Annu Rev Pharmacol Toxicol 1998; 38: 389-430
21. 21. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications [review]. Clin Pharmacokinet 1998; 35: 361-90
22. 22. Silverman RB. Mechanism-based enzyme inactivators. Methods Enzymol 1995; 249: 240-83
23. 23. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-90
24. 24. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyle CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33
25. 25. Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-71
26. 26. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-53
27. 27. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 5: 415-9
28. 28. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
29. 29. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997; 96: 144-6
30. 30. Rampe D, Roy ML, Dennis A, et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32
31. 31. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65: 10-20
32. 32. Zimmermann M, Duruz H, Guinand O, et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002-3
33. 33. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445-6
34. 34. Pohjola-Sintonen S, Viitasalo M, Toivonene L, et al. Torsades de pointes after terfenadine-itraconazole interaction [published erratum in BMJ 1993 Feb 6; 306 (6874): 374]. BMJ 1993; 306: 186
35. 35. Nattel S, Talajic M, Beaudoin D, et al. Absence of pharmacokinetic interaction between amiodarone and lidocaine. Am J Cardiol 1994; 73: 92-4
36. 36. Paris DG, Parente TF, Bruschetta HR, et al. Torsades de pointes induced by erythromycin and terfenadine [review]. Am J Emerg Med 1994; 12: 636-8
37. 37. Hsieh MH, Chen SA, Chiang CE, et al. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol 1996; 54: 85-8
38. 38. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131: 472-80
39. 39. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia [letter]. N Engl J Med 1996; 335: 290-1
40. 40. Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia: torsade de pointes. A case report. Angiology 1997; 48: 821-6
41. 41. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30: 437-9
42. 42. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61: 395-400
43. 43. Thomas AR, Chan LN, Bauman JL, et al. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18: 381-5
44. 44. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33: 22-6
45. 45. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-8
46. 46. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8
47. 47. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-8
48. 48. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 1201-6
49. 49. Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36: 345-51
50. 50. Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61: 401-9
51. 51. Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52: 311-5
52. 52. Gross AS, Goh YD, Addison RS, et al. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999; 65: 395-401
53. 53. Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines [review]. Int J Clin Pharmacol Ther 1998; 36: 292-300
54. 54. Markham A, Wagstaff AJ. Fexofenadine [review]. Drugs 1998; 55: 269-74
55. 55. Honig PK, Worham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53: 630-6
56. 56. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-8
57. 57. Baciewicz AM, Baciewicz Jr FA. Ketoconazole and fluconazole drug interactions [see comments] [review]. Arch Intern Med 1993; 153: 1970-6
58. 58. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993; 27: 427-30
59. 59. Assan R, Fredj G, Larger E, et al. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994; 20: 49-52
60. 60. Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58: 310-5
61. 61. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1988; 109: 682-3
62. 62. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41
63. 63. Biesenbach G, Janko O, Stuby U, et al. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant 1996; 11: 2059-60
64. 64. Hino I, Akama H, Furuya T, et al. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum 1996; 39: 1259-60
65. 65. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? [review]. Pharmacol Ther 1998; 80: 1-34
66. 66. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118-27
67. 67. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65
68. 68. Donahue S, Lachman L, Norton J, et al. Mibefradil significantly increases serum concentrations of atorvastatin but not pravastatin [abstract]. Clin Pharmacol Ther 1999; 65: 179
69. 69. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251-61
70. 70. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
71. 71. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
72. 72. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-77
73. 73. Donahue S, Lachman L, Norton J, et al. Verapamil significantly increases serum concentrations of simvastatin but not pravastatin [abstract]. Clin Pharmacol Ther 1999; 65: 179
74. 74. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-83
75. 75. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82
76. 76. Liedholm H, Nordin G. Erythromycin-felodipine interaction [letter]. DICP 1991; 25: 1007-8
77. 77. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995; 33: 134-5
78. 78. Tailor SA, Gupta AK, Walker SE, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report [letter]. Arch Dermatol 1996; 132: 350-2
79. 79. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189-93
80. 80. Vincent JC, Foulds G, Dogolo LC, et al. Grapefruit juice does not alter the pharmacokinetics of amlodipine in man [abstract]. Clin Pharmacol Ther 1999; 61: 233
81. 81. Madsen JK, Jensen JD, Jensen LW, et al. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 1996; 50: 203-8
82. 82. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60: 25-33
83. 83. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in healthy seniors [abstract]. Clin Pharmacol Ther 1999; 65: 192
84. 84. Bailey DG, Arnold JM, Munoz C, et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-42
85. 85. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
86. 86. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42: 313-7
87. 87. Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995; 49: 61-7
88. 88. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-5
89. 89. Uno T, Ohkubo T, Sugawara K, et al. Effect of grapefruit juice on the disposition of nicardipine after administration of intravenous and oral doses [abstract]. Clin Pharmacol Ther 1999; 61: 209
90. 90. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-8
91. 91. Sigusch H, Hippius M, Henschel L, et al. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 1994; 49: 522-4
92. 92. Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36: 126-32
93. 93. Bailey DG, Arnold JM, Strong HA, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54: 589-94
94. 94. Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50: 394-403
95. 95. Bailey DG, Munoz C, Arnold JM, et al. Grapefruit juice and naringin interaction with nitrendipine [abstract]. Clin Pharmacol Ther 1992; 51: 156
96. 96. Hashimoto K, Shirafuji T, Sekino H, et al. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine-calcium antagonist, in healthy subjects. Eur J Clin Pharmacol 1998; 54: 753-60
97. 97. Billups SJ, Carter BL. Mibefradil: a new class of calcium-channel antagonists [review]. Ann Pharmacother 1998; 32: 659-71
98. 98. Mullins ME, Horowitz BZ, Linden DH, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280: 157-8
99. 99. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction [review]. Drugs 1999; 57: 967-89
100. 100. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310
101. 101. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-8C
102. 102. Cheitlin MD, Hutter AMJ, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College Cardiology/American Heart Association [review]. J Am Coll Cardiol 1999; 33: 273-82
103. 103. Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy [letter]. Lancet 1999; 353: 840
104. 104. Hall MC, Ahmad S. Interaction between sildenafil and HIV-I combination therapy [letter]. Lancet 1999; 353: 2071-2
105. 105. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305
106. 106. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-7
107. 107. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-9
108. 108. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996; 59: 514-9
109. 109. Ozdemir M, Aktan Y, Boydag BS, et al. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998; 23: 55-9
110. 110. Aranko K, Luurila H, Backman JT, et al. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994; 38: 363-7
111. 111. Lilja JJ, Kivisto KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64: 655-60
112. 112. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24
113. 113. Backman JT, Kivisto KT, Olkkola KT, et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-8
114. 114. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-5
115. 115. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34: 400-5
116. 116. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-5
117. 117. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-8
118. 118. Luurila H, Olkkola KT, Neuvonen PJ. Lack of interaction of erythromycin with temazepam. Ther Drug Monit 1994; 16: 548-51
119. 119. Luurila H, Olkkola KT, Neuvonen PJ. Interaction between erythromycin and nitrazepam in healthy volunteers. Pharmacol Toxicol 1995; 76: 255-8
120. 120. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995; 15: 409-16
121. 121. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-6
122. 122. Baciewicz AM. Carbamazepine drug interactions [review]. Ther Drug Monit 1986; 8: 305-17
123. 123. Lai AA, Levy RH, Culler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978; 24: 316-23
124. 124. Loìseau P, Guyot M, Pautrizel B, et al. Carbamazepine poisoning caused by carbamazepine-erythromycin interaction [letter]. Presse Med 1985; 14: 162
125. 125. Berrettini WH. A case of erythromycin-induced carbamazepine toxicity [case report]. J Clin Psychiatry 1986; 47: 147
126. 126. Brodie MJ, MacPhee GJ. Carbamazepine neurotoxicity precipitated by diltiazem. BMJ (Clin Res Ed) 1986; 292: 1170-1
127. 127. Maoz E, Grossman E, Thaler M, et al. Carbamazepine neurotoxic reaction after administration of diltiazem. Arch Intern Med 1992; 152: 2503-4
128. 128. Beattie B, Biller J, Mehlhaus B, et al. Verapamil-induced carbamazepine neurotoxicity: a report of two cases. Eur Neurol 1988; 28: 104-5
129. 129. Pearson HJ. Interaction of fluoxetine with carbamazepine [letter]. J Clin Psychiatry 1990; 51: 126
130. 130. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84: 583-4
131. 131. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161-2
132. 132. Ashton AK, Wolin RE. Nefazodone-induced carbamazepine toxicity [letter]. Am J Psychiatry 1996; 153: 733
133. 133. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10-5
134. 134. Barzaghi N, Gatti G, Crema F, et al. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol 1987; 24: 836-8
135. 135. Miles MV, Tennison MB. Erythromycin effects on multiple-dose carbamazepine kinetics. Ther Drug Monit 1989; 11: 47-52
136. 136. Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997; 33: 659-65
137. 137. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine [review]. Headache 1997; 37 Suppl. 1: S15-25
138. 138. Sanders SW, Haering N, Mosberg H, et al. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986; 30: 331-4
139. 139. Tfelt-Hansen P, Paalzow L, Ibraheem JJ. Bioavailability of sublingual ergotamine. Br J Clin Pharmacol 1982; 13: 239-40
140. 140. Ekbom K, Paalzow L, Waldenlind E. Low biological availability of ergotamine tartrate after oral dosing in cluster headache. Cephalalgia 1981; 1: 203-7
141. 141. Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. Arch Intern Med 1996; 156: 456-8
142. 142. Caballero-Granado FJ, Viciana P, Cordero E, et al. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient [letter]. Antimicrob Agents Chemother 1997; 41: 1207
143. 143. Liaudet L, Buclin T, Jaccard C, et al. Drug points: severe ergotism associated with interaction between ritonavir and ergotamine [case report]. BMJ (Clin Res Ed) 1999; (7186): 7711
144. 144. Hayton AC. Precipitation of acute ergotism by triacetyloleandomycin [case report]. N Z Med J 1969; 69: 42
145. 145. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-9
146. 146. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000-4
147. 147. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
148. 148. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-91
149. 149. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57: 318-24
150. 150. Min DI, Ku YM, Perry PJ, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996; 62: 123-5
151. 151. Ioannides-Demos LL, Christophidis N, Ryan P, et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol 1997; 24: 49-54
152. 152. Brunner LJ, Munar MY, Vallian J, et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18: 23-9
153. 153. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations [review]. Clin Pharmacokinet 1997; 32: 194-209
154. 154. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4
155. 155. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-9
156. 156. Merry C, Barry MG, Muleahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-F33
157. 157. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-9
158. 158. Blychert E, Edgar B, Elmfeldt D, et al. Plasma concentration-effect relationships for felodipine: a meta analysis. Clin Pharmacol Ther 1992; 52: 80-9
159. 159. Furberg CD, Psaty BM. Corrections to the nifedipine meta-analysis [letter]. Circulation 1996; 93: 1475-6
160. 160. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31
161. 161. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397-402
162. 162. Rogers JD, Vega JM, Zhao J, et al. Grapefruit juice (GFJ) has a small effect on lovastatin plasma HMG-CoA reductase inhibitor (HMGR1) profiles [abstract]. Clin Pharmacol Ther 1999; 65: 149